Appendix

Classification of COVID-19 disease severity

The severity of COVID-19 was classified according to the WHO guidelines. Patients with COVID-19 were divided into five subtypes according to the degree of disease severity. Asymptomatic patients were those who were only tested positive for COVID-19 but did not show any clinical, biochemical, or radiological features of the disease. The mild type was defined as having mild clinical symptoms without hypoxia or infiltrates on radiography. The moderate type was defined as fever and/or respiratory symptoms plus lung infiltrates on radiography. The severe type was diagnosed based on clinical and radiological signs of pneumonia (fever, cough, dyspnea, tachypnea, infiltrates on chest x-ray) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air, artery PaO2/FiO2<300 mm Hg (1 mm Hg=0.133 kPa).

				J I			0 1		
		Diarrhea	Nausea	Vomiting	Epigastric	GERD	Anorexia	GIB	Any GI
					pain				
Group	1	73	158	148	57 (10.9%)	6	51 (9.7%)	11	202
(524)		(13.9%)	(30.2%)	(28.2%)		(1.1%)		(2.1%)	(38.5%)
<i>P</i> -value		0.49	0.51	0.13	1.00	1.00	0.07	1.00	0.26
Group	2	58	134	126	47 (10.9%)	6	43	9	169
(431)		(13.5%)	(31.1%)	(29.2%)		(1.4%)	(10.0%)	(2.1%)	(39.2%)
<i>P</i> -value		0.37	0.23	0.07	1.00	0.19	0.38	1.00	0.22
Group	3	37	103	102	37 (12.1%)	4	36	8	126
(307)		(12.1%)	(33.6%)	(33.2%)		(1.3%)	(11.7%)	(2.6%)	(41.0%)
<i>P</i> -value		0.13	0.032 ^a	0.001 ^a	0.36	0.69	0.43	0.38	0.08
Group	4	24	60	59	23 (12.7%)	4	22	6	72
(181)		(13.3%)	(33.1%)	(32.6%)		(2.2%)	(12.2%)	(3.3%)	(39.8%)
<i>P</i> -value		0.70	0.24	0.057	0.32	0.070	0.47	0.199	0.521
Group 5 (61))	13	19	16	10 (16.4%)	2	13	1(1.6%)	27
		(21.3%)	(31.1%)	(26.2%)		(3.3%)	(21.3%)		(44.3%)
<i>P</i> -value		0.078	0.76	1.00	0.188	0.12	0.008 ^a	1.00	0.27
Group 6 (56))	11	17	15	8 (14.3%)	2	12	1	24
		(19.6%)	(30.4%)	(26.8%)		(3.6%)	(21.4%)	(1.8%)	(42.9%)
<i>P</i> -value		0.23	0.88	1.00	0.37	0.10	0.01 ^a	1.00	0.47

Supplementary Tables

 Table 1 Association of GI symptoms with different Treatment groups

	Univariate Analysis		
Risk Factors	Odds ratio	P-value	
	Death		
Age > 65 yrs	8.64 (3.94-18.95)	< 0.001	
Sore throat	0.19 (0.04-0.80)	0.024	
HTN	2.92 (1.44-5.91)	0.003	
CAD	3.48 (1.43-8.50)	0.006	
CKD	2.78 (1.09-7.12)	0.032	
	Disease severity at pr	esentation	
GI symptoms	1.72 (1.66-2.55)	0.006	
Smoking	1.94 (1.23-2.06)	0.004	
HTN	2.04 (1.39-2.96)	<0.001	
DM	2.30 (1.59-3.33)	<0.001	
	ICU admission		
Age > 65 yrs	2.09 (1.45-3.01)	<0.001	
Gender (male)	1.90 (1.17-3.10)	0.009	
Fever	3.30 (2.07-5.25)	<0.001	
Cough	2.25 (1.50-3.37)	<0.001	
Myalgias	1.52 (1.07-1.16)	0.018	
HTN	2.05 (1.45-2.88)	<0.001	
DM	1.76 (1.27-2.46)	0.001	
	Mechanical ventilatio	n	
Age > 65 yr	2.09 (1.43-3.04)	<0.001	
Gender (male)	1.92 (1.10-3.33)	0.02	
Fever	4.30 (2.39-74)	<0.001	
Cough	2.35 (1.48-3.73)	<0.001	
Cough	2.33 (1.46-3.73)	\0.001	

Table 2 Univariate analysis of risk factors for severe COVID-19 at presentation andClinical Outcomes

Shortness of breath	3.25 (2.24-4.71)	<0.001
HTN	1.91 (1.33-2.73)	<0.001
DM	1.53 (1.07-2.17)	0.018